The finding that individuals lacking CCR5 expression due to a homozygous deletion in the ccr5 gene (CCR5/Δ32) are resistant to HIV-1 infection without suffering from adverse effects [9] stimulated the search for HIV inhibitory CCR5 antagonists, which culminated in the approval of the compound Maraviroc (MVC) [10] for clinical use. Here, CCR5 is linked to HIV-1 infection.